An observational study in Helicobacter Pylori Infection and Antibiotic Resistant Strain, sponsored by Kangdong Sacred Heart Hospital. Completed. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-21.
Sponsored by Kangdong Sacred Heart Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.
Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant.
Participants who did not have point mutations related to clarithromycin resistance and/or had clinically insignificant point mutations were treated with PAC (proton pump inhibitor, amoxicillin, clarithromycin) for 7 days, while participants with clinically significant point mutations were treated with PAM (proton pump inhibitor, amoxicillin, metronidazole) for 7 days. H. pylori eradication rates were compared between the two groups.
246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.
This study's enrollment of 431 is above the median of 101 across 79 observational studies indexed under Sprains and Strains.
Browse Sprains and Strains studies →Kangdong Sacred Heart Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Helicobacter-pylori positive patients with gastritis, ulcer, adenoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
Drug: proton pump inhibitor, amoxicillin, metronidazole
Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
Drug: proton pump inhibitor, amoxicillin, clarithromycin
Drug pages: Proton pump inhibitors (PPIs)Studies of Proton pump inhibitors (PPIs)Proton pump inhibitors (PPIs) pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClarithromycinStudies of ClarithromycinClarithromycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
Drug pages: Proton pump inhibitors (PPIs)Studies of Proton pump inhibitors (PPIs)Proton pump inhibitors (PPIs) pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetronidazoleStudies of MetronidazoleMetronidazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
Helicobacter pylori eradication rate
Number of participant with successful Helicobacter pylori eradication
Time frame: 2 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Dec 2018, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kangdong Sacred Heart Hospital